{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:39:27Z","timestamp":1776847167992,"version":"3.51.2"},"reference-count":231,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["RAIAD"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Psoriasis is a relapsing, chronic, and inflammatory disease of the skin. However, its\nimpact goes beyond just pathophysiology and takes a toll on the physical and psychological aspects\nof the health of the afflicted, lowering the quality of life significantly. It is also a mechanistically\ncomplex disease with a substantial immune component. Therefore, ongoing treatment\nstrategies focus on targeting at least one immune component associated with the disease development\nand progression by employing biological agents like IL-1 inhibitors, IL-23 inhibitors,\nIL-36 inhibitors, and TNF-&amp;#945; inhibitors. Psoriasis-induced disruptions in cellular signalling\npathways have drawn significant attention as novel drug targets. Numerous novel synthetic\nagents, such as JAK\/STAT inhibitors (ruxolitinib, peficitinib), TYK2 inhibitors [zasocitinib,\nropsacitinib], ROR\u03b3T inhibitors (cedirogant), A3AR agonists (piclodenoson), and CXCR2 antagonists\n(vimnerixin) are undergoing extensive clinical trials and have demonstrated beneficial\noutcomes in multiple phases of these trials. Deucravacitinib, an orally administered TYK2 inhibitor,\nhas recently received FDA approval for the treatment of moderate to severe plaque psoriasis.\nThese synthetic agents hold promise to change the outlook of psoriasis management by\nmodulating specific molecular targets associated with the dysregulated immune response observed\nin psoriasis. Moreover, these pathways can be exploited to personalize anti-psoriatic\ntherapy, minimize side effects, and maximize therapeutic outcomes. Altogether, the integration\nof biological agents and synthetic agents can overcome the challenges associated with the management\nof the repertoire of psoriatic pathophysiology and symptoms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0127722708338282250309081129","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T04:17:06Z","timestamp":1743653826000},"page":"101-126","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacological Management of Psoriasis: Current Landscape and Future Perspectives"],"prefix":"10.2174","volume":"20","author":[{"given":"Roopal","family":"Pedwar","sequence":"first","affiliation":[{"name":"Amity Institute of Pharmacy, Amity University Campus, Sector-125, Noida, 201301, Gautam Buddha Nagar, UttarPradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anush","family":"Tomar","sequence":"additional","affiliation":[{"name":"College of Pharmacy (Orlando Campus), University of Florida, 6550 Sanger Rd, Orlando, FL 32827,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2140-9270","authenticated-orcid":true,"given":"Sweta","family":"Bawari","sequence":"additional","affiliation":[{"name":"Amity Institute of Pharmacy, Amity University Campus, Sector-125, Noida, 201301, Gautam Buddha Nagar, UttarPradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"105678","DOI":"10.1016\/j.phrs.2021.105678","volume":"169","author":"Qi Q.","year":"2021","unstructured":"Qi Q.; Li Q.; Zhu H.; Triptolide analog LLDT-8 ameliorates psoriasis-like dermatitis in BALB\/c mice via suppressing the IL-36\u03b1 signaling pathway. Pharmacol Res  2021,169,105678","journal-title":"Pharmacol Res"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"107754","DOI":"10.1016\/j.intimp.2021.107754","volume":"96","author":"Sangaraju R.","year":"2021","unstructured":"Sangaraju R.; Alavala S.; Nalban N.; Jerald M.K.; Sistla R.; Galangin ameliorates Imiquimod-Induced psoriasis-like skin inflammation in BALB\/c mice via down regulating NF-\u03baB and activation of Nrf2 signaling pathways. Int Immunopharmacol  2021,96,107754","journal-title":"Int Immunopharmacol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"119630","DOI":"10.1016\/j.lfs.2021.119630","volume":"278","author":"Zhang R.","year":"2021","unstructured":"Zhang R.; Wang Y.H.; Shi X.; Ji J.; Zhan F.Q.; Leng H.; Sortilin regulates keratinocyte proliferation and apoptosis through the PI3K-AKT signaling pathway. Life Sci  2021,278,119630","journal-title":"Life Sci"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","volume":"370","author":"Griffiths C.E.M.","year":"2007","unstructured":"Griffiths C.E.M.; Barker J.N.W.N.; Pathogenesis and clinical features of psoriasis. Lancet  2007,370(9583),263-271","journal-title":"Lancet"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"107900","DOI":"10.1016\/j.intimp.2021.107900","volume":"99","author":"Di T.","year":"2021","unstructured":"Di T.; Zhai C.; Zhao J.; Wang Y.; Chen Z.; Li P.; Taxifolin inhibits keratinocyte proliferation and ameliorates imiquimod-induced psoriasis-like mouse model via regulating cytoplasmic phospholipase A2 and PPAR-\u03b3 pathway. Int Immunopharmacol  2021,99,107900","journal-title":"Int Immunopharmacol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1365-2133.2012.11215.x","volume":"168","author":"Sigurdardottir S.L.","year":"2013","unstructured":"Sigurdardottir S.L.; Thorleifsdottir R.H.; Valdimarsson H.; Johnston A.; The role of the palatine tonsils in the pathogenesis and treatment of psoriasis. Br J Dermatol  2013,168(2),237-242","journal-title":"Br J Dermatol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.clindermatol.2007.08.015","volume":"25","author":"Fry L.","year":"2007","unstructured":"Fry L.; Baker B.S.; Triggering psoriasis: The role of infections and medications. Clin Dermatol  2007,25(6),606-615","journal-title":"Clin Dermatol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jaci.2016.08.056","volume":"140","author":"Johnston A.","year":"2017","unstructured":"Johnston A.; Xing X.; Wolterink L.; IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol  2017,140(1),109-120","journal-title":"J Allergy Clin Immunol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/j.1365-4632.2010.04570.x","volume":"49","author":"Basavaraj K.H.","year":"2010","unstructured":"Basavaraj K.H.; Ashok N.M.; Rashmi R.; Praveen T.K.; The role of drugs in the induction and\/or exacerbation of psoriasis. Int J Dermatol  2010,49(12),1351-1361","journal-title":"Int J Dermatol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/HNP.0000000000000180","volume":"32","author":"Ljubenovic M.","year":"2018","unstructured":"Ljubenovic M.; Lazarevic V.; Golubovic M.; Binic I.; Integrative approach to Psoriasis Vulgaris. Holist Nurs Pract  2018,32(3),133-139","journal-title":"Holist Nurs Pract"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1016\/j.jid.2016.07.008","volume":"136","author":"Xing X.","year":"2016","unstructured":"Xing X.; Liang Y.; Sarkar M.K.; IL-17 responses are the dominant inflammatory signal linking inverse, erythrodermic, and chronic Plaque Psoriasis. J Invest Dermatol  2016,136(12),2498-2501","journal-title":"J Invest Dermatol"},{"key":"ref=12","author":"Saleh D.","year":"2023","unstructured":"Saleh D.; Tanner L.S.;  In: StatPearls  2023","journal-title":"In: StatPearls"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s00105-015-3628-7","volume":"66","author":"Weisenseel P.","year":"2015","unstructured":"Weisenseel P.; Reich K.; Psoriasis inversa. Hautarzt  2015,66(6),408-412","journal-title":"Hautarzt"},{"key":"ref=14","first-page":"119","volume":"7","author":"Ni C.","year":"2014","unstructured":"Ni C.; Chiu M.W.; Psoriasis and comorbidities: Links and risks. Clin Cosmet Investig Dermatol  2014,7,119-132","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/jid.2010.103","volume":"130","author":"Davidovici B.B.","year":"2010","unstructured":"Davidovici B.B.; Sattar N.; J\u00f6rg P.C.; Psoriasis and systemic inflammatory diseases: Potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol  2010,130(7),1785-1796","journal-title":"J Invest Dermatol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3390\/ijms21020434","volume":"21","author":"Furue K.","year":"2020","unstructured":"Furue K.; Ito T.; Tanaka Y.; The EGFR-ERK\/JNK-CCL20 pathway in scratched keratinocytes may underpin koebnerization in psoriasis patients. Int J Mol Sci  2020,21(2),434","journal-title":"Int J Mol Sci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/jid.2011.259","volume":"132","author":"Morizane S.","year":"2012","unstructured":"Morizane S.; Yamasaki K.; M\u00fchleisen B.; Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands. J Invest Dermatol  2012,132(1),135-143","journal-title":"J Invest Dermatol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","volume":"182","author":"van der Fits L.","year":"2009","unstructured":"van der Fits L.; Mourits S.; Voerman J.S.A.; Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis. J Immunol  2009,182(9),5836-5845","journal-title":"J Immunol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"7104","DOI":"10.4049\/jimmunol.176.11.7104","volume":"176","author":"Diluvio L.","year":"2006","unstructured":"Diluvio L.; Vollmer S.; Besgen P.; Ellwart J.W.; Chimenti S.; Prinz J.C.; Identical TCR beta-chain rearrangements in streptococcal angina and skin lesions of patients with psoriasis vulgaris. J Immunol  2006,176(11),7104-7111","journal-title":"J Immunol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1346-8138.2011.01483.x","volume":"39","author":"Morizane S.","year":"2012","unstructured":"Morizane S.; Gallo R.L.; Antimicrobial peptides in the pathogenesis of psoriasis. J Dermatol  2012,39(3),225-230","journal-title":"J Dermatol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"e1139","DOI":"10.1002\/cti2.1139","volume":"9","author":"Ye Y.","year":"2020","unstructured":"Ye Y.; Gaugler B.; Mohty M.; Malard F.; Plasmacytoid dendritic cell biology and its role in immune\u2010mediated diseases. Clin Transl Immunology  2020,9(5),e1139","journal-title":"Clin Transl Immunology"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1084\/jem.20050500","volume":"202","author":"Nestle F.O.","year":"2005","unstructured":"Nestle F.O.; Conrad C.; Tun-Kyi A.; Plasmacytoid predendritic cells initiate psoriasis through interferon-\u03b1 production. J Exp Med  2005,202(1),135-143","journal-title":"J Exp Med"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jaci.2010.12.009","author":"H\u00e4nsel A.","year":"2011","unstructured":"H\u00e4nsel A.; G\u00fcnther C.; Ingwersen J.; Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong TH17\/TH1 T-cell responses. J Allergy Clin Immunol  2011(3),787-794","journal-title":"J Allergy Clin Immunol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nri2586","volume":"9","author":"Gaffen S.L.","year":"2009","unstructured":"Gaffen S.L.; Structure and signalling in the IL-17 receptor family. Nat Rev Immunol  2009,9(8),556-567","journal-title":"Nat Rev Immunol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1111\/jdv.14433","volume":"31","author":"Girolomoni G.","year":"2017","unstructured":"Girolomoni G.; Strohal R.; Puig L.; The role of IL \u201023 and the IL \u201023\/T H 17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol  2017,31(10),1616-1626","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1182\/blood-2006-05-021600","volume":"109","author":"Fr\u00f6hlich A.","year":"2007","unstructured":"Fr\u00f6hlich A.; Marsland B.J.; Sonderegger I.; IL-21 receptor signaling is integral to the development of Th2 effector responses in vivo. Blood  2007,109(5),2023-2031","journal-title":"Blood"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1749-6632.2009.05152.x","volume":"1183","author":"Lande R.","year":"2010","unstructured":"Lande R.; Gilliet M.; Plasmacytoid dendritic cells: Key players in the initiation and regulation of immune responses. Ann N Y Acad Sci  2010,1183(1),89-103","journal-title":"Ann N Y Acad Sci"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/jid.2011.468","volume":"132","author":"Tohyama M.","year":"2012","unstructured":"Tohyama M.; Yang L.; Hanakawa Y.; Dai X.; Shirakata Y.; Sayama K.; IFN-\u03b1 enhances IL-22 receptor expression in keratinocytes: A possible role in the development of psoriasis. J Invest Dermatol  2012,132(7),1933-1935","journal-title":"J Invest Dermatol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/1346-8138.12367","volume":"41","author":"Ueyama A.","year":"2014","unstructured":"Ueyama A.; Yamamoto M.; Tsujii K.; Mechanism of pathogenesis of imiquimod\u2010induced skin inflammation in the mouse: A role for interferon\u2010alpha in dendritic cell activation by imiquimod. J Dermatol  2014,41(2),135-143","journal-title":"J Dermatol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/imm.12888","volume":"154","author":"Collin M.","year":"2018","unstructured":"Collin M.; Bigley V.; Human dendritic cell subsets: An update. Immunology  2018,154(1),3-20","journal-title":"Immunology"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"15258","DOI":"10.1074\/jbc.272.24.15258","volume":"272","author":"Frohm M.","year":"1997","unstructured":"Frohm M.; Agerberth B.; Ahangari G.; The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J Biol Chem  1997,272(24),15258-15263","journal-title":"J Biol Chem"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.smim.2007.10.011","volume":"19","author":"Ivanov I.I.","year":"2007","unstructured":"Ivanov I.I.; Zhou L.; Littman D.R.; Transcriptional regulation of Th17 cell differentiation. Semin Immunol  2007,19(6),409-417","journal-title":"Semin Immunol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s13765-017-0285-9","volume":"60","author":"Ranneh Y.","year":"2017","unstructured":"Ranneh Y.; Ali F.; Akim A.M.; Hamid H.A.; Khazaai H.; Fadel A.; Crosstalk between reactive oxygen species and pro-inflammatory markers in developing various chronic diseases: A review. Appl Biol Chem  2017,60(3),327-338","journal-title":"Appl Biol Chem"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1086\/503821","volume":"78","author":"Nair R.P.","year":"2006","unstructured":"Nair R.P.; Stuart P.E.; Nistor I.; Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet  2006,78(5),827-851","journal-title":"Am J Hum Genet"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3390\/ijms19010171","volume":"19","author":"Calautti E.","year":"2018","unstructured":"Calautti E.; Avalle L.; Poli V.; Psoriasis: A STAT3-Centric View. Int J Mol Sci  2018,19(1),171","journal-title":"Int J Mol Sci"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1172\/JCI0215650","volume":"109","author":"Levy D.E.","year":"2002","unstructured":"Levy D.E.; Lee C.; What does Stat3 do? J Clin Invest  2002,109(9),1143-1148","journal-title":"J Clin Invest"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"998","DOI":"10.4049\/jimmunol.180.2.998","volume":"180","author":"Haan S.","year":"2008","unstructured":"Haan S.; Margue C.; Engrand A.; Dual role of the Jak1 FERM and kinase domains in cytokine receptor binding and in stimulation-dependent Jak activation. J Immunol  2008,180(2),998-1007","journal-title":"J Immunol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.bcp.2011.12.024","volume":"83","author":"Seavey M.M.","year":"2012","unstructured":"Seavey M.M.; Dobrzanski P.; The many faces of Janus kinase. Biochem Pharmacol  2012,83(9),1136-1145","journal-title":"Biochem Pharmacol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-2164-14-4","volume":"14","author":"Kang K.","year":"2013","unstructured":"Kang K.; Robinson G.W.; Hennighausen L.; Comprehensive meta-analysis of Signal Transducers and Activators of Transcription (STAT) genomic binding patterns discerns cell-specific cis-regulatory modules. BMC Genomics  2013,14(1),4","journal-title":"BMC Genomics"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"4925","DOI":"10.2741\/3051","volume":"Volume (13)","author":"Xu D","year":"2008","unstructured":"Xu D; Qu CK; Protein tyrosine phosphatases in the JAK\/STAT pathway. Front Biosci  2008,Volume (13),4925-4932","journal-title":"Front Biosci"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1136\/annrheumdis-2016-211046","volume":"76","author":"Raychaudhuri S.K.","year":"2017","unstructured":"Raychaudhuri S.K.; Abria C.; Raychaudhuri S.P.; Regulatory role of the JAK STAT kinase signalling system on the IL-23\/IL-17 cytokine axis in psoriatic arthritis. Ann Rheum Dis  2017,76(10),e36-e37","journal-title":"Ann Rheum Dis"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.3109\/19401736.2015.1053079","volume":"27","author":"Li C.","year":"2016","unstructured":"Li C.; Wang Z.L.; Fang W.Y.; Yu X.P.; The complete mitochondrial genomes of two orb-weaving spider Cyrtarachne nagasakiensis (Strand, 1918) and Hypsosinga pygmaea (Sundevall, 1831) (Araneae: Araneidae). Mitochondrial DNA A DNA Mapp Seq Anal  2016,27(4),2811-2812","journal-title":"Mitochondrial DNA A DNA Mapp Seq Anal"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jdermsci.2007.05.016","volume":"50","author":"Sano S.","year":"2008","unstructured":"Sano S.; Chan K.S.; DiGiovanni J.; Impact of Stat3 activation upon skin biology: A dichotomy of its role between homeostasis and diseases. J Dermatol Sci  2008,50(1),1-14","journal-title":"J Dermatol Sci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"e0164080","DOI":"10.1371\/journal.pone.0164080","volume":"11","author":"Alves de Medeiros A.K.","year":"2016","unstructured":"Alves de Medeiros A.K.; Speeckaert R.; Desmet E.; Van Gele M.; De Schepper S.; Lambert J.; JAK3 as an emerging target for topical treatment of inflammatory skin diseases. PLoS One  2016,11(10),e0164080","journal-title":"PLoS One"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/nm804","volume":"9","author":"Ghoreschi K.","year":"2003","unstructured":"Ghoreschi K.; Thomas P.; Breit S.; Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med  2003,9(1),40-46","journal-title":"Nat Med"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","volume":"32","author":"Lowes M.A.","year":"2014","unstructured":"Lowes M.A.; Su\u00e1rez-Fari\u00f1as M.; Krueger J.G.; Immunology of Psoriasis. Annu Rev Immunol  2014,32(1),227-255","journal-title":"Annu Rev Immunol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nature09447","volume":"467","author":"Ghoreschi K.","year":"2010","unstructured":"Ghoreschi K.; Laurence A.; Yang X.P.; Generation of pathogenic TH17 cells in the absence of TGF-\u03b2 signalling. Nature  2010,467(7318),967-971","journal-title":"Nature"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/eji.201646680","volume":"47","author":"Welsch K.","year":"2017","unstructured":"Welsch K.; Holstein J.; Laurence A.; Ghoreschi K.; Targeting JAK\/STAT signalling in inflammatory skin diseases with small molecule inhibitors. Eur J Immunol  2017,47(7),1096-1107","journal-title":"Eur J Immunol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.biocel.2008.06.010","volume":"41","author":"Aggarwal B.B.","year":"2009","unstructured":"Aggarwal B.B.; Harikumar K.B.; Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol  2009,41(1),40-59","journal-title":"Int J Biochem Cell Biol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"32856","DOI":"10.1074\/jbc.M506119200","volume":"280","author":"Calautti E.","year":"2005","unstructured":"Calautti E.; Li J.; Saoncella S.; Brissette J.L.; Goetinck P.F.; Phosphoinositide 3-kinase signaling to Akt promotes keratinocyte differentiation versus death. J Biol Chem  2005,280(38),32856-32865","journal-title":"J Biol Chem"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1042\/bst0310292","volume":"31","author":"Birkenkamp K.U.","year":"2003","unstructured":"Birkenkamp K.U.; Coffer P.J.; Regulation of cell survival and proliferation by the FOXO (Forkhead box, class O) subfamily of Forkhead transcription factors. Biochem Soc Trans  2003,31(1),292-297","journal-title":"Biochem Soc Trans"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1016\/j.bbamcr.2011.03.010","volume":"1813","author":"Zhang X.","year":"2011","unstructured":"Zhang X.; Tang N.; Hadden T.J.; Rishi A.K.; Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta Mol Cell Res  2011,1813(11),1978-1986","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"155657","DOI":"10.1016\/j.cyto.2021.155657","volume":"148","author":"Tang Z.L.","year":"2021","unstructured":"Tang Z.L.; Zhang K.; Lv S.C.; Xu G.W.; Zhang J.F.; Jia H.Y.; LncRNA MEG3 suppresses PI3K\/AKT\/mTOR signalling pathway to enhance autophagy and inhibit inflammation in TNF-\u03b1-treated keratinocytes and psoriatic mice. Cytokine  2021,148,155657","journal-title":"Cytokine"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.2147\/CCID.S389760","volume":"15","author":"Li L.","year":"2022","unstructured":"Li L.; Lu H.; Zhang Y.; Li Q.; Shi S.; Liu Y.; Effect of azelaic acid on psoriasis progression investigated based on Phosphatidylinositol 3-Kinase (PI3K)\/Protein Kinase B (AKT) signaling pathway. Clin Cosmet Investig Dermatol  2022,15,2523-2534","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"102435","DOI":"10.1016\/j.jaut.2020.102435","volume":"111","author":"Chen S.","year":"2020","unstructured":"Chen S.; Paveley R.; Kraal L.; Selective targeting of PI3K\u03b4 suppresses human IL-17-producing T cells and innate-like lymphocytes and may be therapeutic for IL-17-mediated diseases. J Autoimmun  2020,111,102435","journal-title":"J Autoimmun"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.biopha.2017.12.073","volume":"98","author":"Tan F.","year":"2018","unstructured":"Tan F.; Yang G.; Wang Y.; Icotinib inhibits EGFR signaling and alleviates psoriasis-like symptoms in animal models. Biomed Pharmacother  2018,98,399-405","journal-title":"Biomed Pharmacother"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"823","DOI":"10.2353\/ajpath.2006.050449","volume":"169","author":"Xu Y.","year":"2006","unstructured":"Xu Y.; Voorhees J.J.; Fisher G.J.; Epidermal growth factor receptor is a critical mediator of ultraviolet B irradiation-induced signal transduction in immortalized human keratinocyte HaCaT cells. Am J Pathol  2006,169(3),823-830","journal-title":"Am J Pathol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1111\/j.1365-2133.2010.09990.x","volume":"163","author":"Anderson K.S.","year":"2010","unstructured":"Anderson K.S.; Petersson S.; Wong J.; Elevation of serum epidermal growth factor and interleukin 1 receptor antagonist in active psoriasis vulgaris. Br J Dermatol  2010,163(5),1085-1089","journal-title":"Br J Dermatol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jid.2020.07.030","volume":"141","author":"Kelel M.","year":"2021","unstructured":"Kelel M.; Yang R.B.; Tsai T.F.; FUT8 remodeling of EGFR regulates epidermal keratinocyte proliferation during Psoriasis development. J Invest Dermatol  2021,141(3),512-522","journal-title":"J Invest Dermatol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"e923","DOI":"10.1038\/cddis.2013.450","volume":"4","author":"Cheng L.","year":"2013","unstructured":"Cheng L.; Luo S.; Jin C.; Ma H.; Zhou H.; Jia L.; FUT family mediates the multidrug resistance of human hepatocellular carcinoma via the PI3K\/Akt signaling pathway. Cell Death Dis  2013,4(11),e923","journal-title":"Cell Death Dis"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1152\/physrev.00028.2011","volume":"92","author":"Kyriakis J.M.","year":"2012","unstructured":"Kyriakis J.M.; Avruch J.; Mammalian MAPK signal transduction pathways activated by stress and inflammation: A 10-year update. Physiol Rev  2012,92(2),689-737","journal-title":"Physiol Rev"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/13510002.2019.1658377","volume":"24","author":"Xu F.","year":"2019","unstructured":"Xu F.; Xu J.; Xiong X.; Deng Y.; Salidroside inhibits MAPK, NF-\u03baB, and STAT3 pathways in psoriasis-associated oxidative stress via SIRT1 activation. Redox Rep  2019,24(1),70-74","journal-title":"Redox Rep"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jphs.2023.12.007","volume":"154","author":"Su Z.","year":"2024","unstructured":"Su Z.; Kang Y.; Protective effect and regulatory mechanism of salidroside on skin inflammation induced by imiquimod in psoriasis mice. J Pharmacol Sci  2024,154(3),192-202","journal-title":"J Pharmacol Sci"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/569751","volume":"2013","author":"Mavropoulos A.","year":"2013","unstructured":"Mavropoulos A.; Rigopoulou E.I.; Liaskos C.; Bogdanos D.P.; Sakkas L.I.; The role of p38 MAPK in the aetiopathogenesis of psoriasis and psoriatic arthritis. Clin Dev Immunol  2013,2013,1-8","journal-title":"Clin Dev Immunol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.4049\/jimmunol.176.3.1431","volume":"176","author":"Johansen C.","year":"2006","unstructured":"Johansen C.; Funding A.T.; Otkjaer K.; Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2. J Immunol  2006,176(3),1431-1438","journal-title":"J Immunol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"10782","DOI":"10.3390\/ijms241310782","volume":"24","author":"S\u0142uczanowska-G\u0142abowska S.","year":"2023","unstructured":"S\u0142uczanowska-G\u0142abowska S.; Salmanowicz M.; Staniszewska M.; Pawlik A.; The role of sirtuins in the pathogenesis of psoriasis. Int J Mol Sci  2023,24(13),10782","journal-title":"Int J Mol Sci"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/j.1600-065X.2008.00744.x","volume":"228","author":"Rinc\u00f3n M.","year":"2009","unstructured":"Rinc\u00f3n M.; Davis R.J.; Regulation of the immune response by stress\u2010activated protein kinases. Immunol Rev  2009,228(1),212-224","journal-title":"Immunol Rev"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jdermsci.2012.10.018","volume":"69","author":"Chen L.","year":"2013","unstructured":"Chen L.; Wu J.; Ren W.; Yang X.; Shen Z.; c-Jun N-terminal kinase (JNK)-phospho-c-JUN (ser63\/73) pathway is essential for FOXP3 nuclear translocation in psoriasis. J Dermatol Sci  2013,69(2),114-121","journal-title":"J Dermatol Sci"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"20530","DOI":"10.1074\/jbc.M602712200","volume":"281","author":"Gazel A.","year":"2006","unstructured":"Gazel A.; Banno T.; Walsh R.; Blumenberg M.; Inhibition of JNK promotes differentiation of epidermal keratinocytes. J Biol Chem  2006,281(29),20530-20541","journal-title":"J Biol Chem"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3390\/cells9040857","volume":"9","author":"Hammouda M.","year":"2020","unstructured":"Hammouda M.; Ford A.; Liu Y.; Zhang J.; The JNK signaling pathway in inflammatory skin disorders and cancer. Cells  2020,9(4),857","journal-title":"Cells"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1046\/j.1523-1747.2000.00934.x","volume":"114","author":"Peus D.","year":"2000","unstructured":"Peus D.; Beyerle A.; Pott M.; Anti-psoriatic drug anthralin activates JNK via lipid peroxidation: Mononuclear cells are more sensitive than keratinocytes. J Invest Dermatol  2000,114(4),688-692","journal-title":"J Invest Dermatol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1089\/ars.2006.8.1775","volume":"8","author":"McCubrey J.A.","year":"2006","unstructured":"McCubrey J.A.; LaHair M.M.; Franklin R.A.; Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxid Redox Signal  2006,8(9-10),1775-1789","journal-title":"Antioxid Redox Signal"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3109\/10715762.2016.1162301","volume":"50","author":"Lin X.","year":"2016","unstructured":"Lin X.; Huang T.; Oxidative stress in psoriasis and potential therapeutic use of antioxidants. Free Radic Res  2016,50(6),585-595","journal-title":"Free Radic Res"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.3389\/fimmu.2019.01764","volume":"10","author":"Sch\u00f6n M.P.","year":"2019","unstructured":"Sch\u00f6n M.P.; Adaptive and innate immunity in psoriasis and other inflammatory disorders. Front Immunol  2019,10,1764","journal-title":"Front Immunol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jdermsci.2012.11.002","volume":"69","author":"Goldminz A.M.","year":"2013","unstructured":"Goldminz A.M.; Au S.C.; Kim N.; Gottlieb A.B.; Lizzul P.F.; NF-\u03baB: An essential transcription factor in psoriasis. J Dermatol Sci  2013,69(2),89-94","journal-title":"J Dermatol Sci"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1038\/s41598-019-38778-2","volume":"9","author":"Nguyen T.T.","year":"2019","unstructured":"Nguyen T.T.; Ung T.T.; Li S.; Metformin inhibits lithocholic acid-induced interleukin 8 upregulation in colorectal cancer cells by suppressing ROS production and NF-kB activity. Sci Rep  2019,9(1),2003","journal-title":"Sci Rep"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"7454","DOI":"10.1038\/ncomms8454","volume":"6","author":"Hara-Chikuma M.","year":"2015","unstructured":"Hara-Chikuma M.; Satooka H.; Watanabe S.; Aquaporin-3-mediated hydrogen peroxide transport is required for NF-\u03baB signalling in keratinocytes and development of psoriasis. Nat Commun  2015,6(1),7454","journal-title":"Nat Commun"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"6206","DOI":"10.3390\/ijms21176206","volume":"21","author":"Ple\u0144kowska J.","year":"2020","unstructured":"Ple\u0144kowska J.; Gabig-Cimi\u0144ska M.; Mozolewski P.; Oxidative stress as an important contributor to the pathogenesis of psoriasis. Int J Mol Sci  2020,21(17),6206","journal-title":"Int J Mol Sci"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.biopha.2018.07.156","volume":"107","author":"Pradhan M.","year":"2018","unstructured":"Pradhan M.; Alexander A.; Singh M.R.; Understanding the prospective of nano-formulations towards the treatment of psoriasis. Biomed Pharmacother  2018,107,447-463","journal-title":"Biomed Pharmacother"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1208\/s12249-021-02057-z","volume":"22","author":"Biswasroy P.","year":"2021","unstructured":"Biswasroy P.; Pradhan D.; Kar B.; Ghosh G.; Rath G.; Recent advancement in topical nanocarriers for the treatment of psoriasis. AAPS PharmSciTech  2021,22(5),164","journal-title":"AAPS PharmSciTech"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s10856-021-06558-y","volume":"32","author":"Shetty K.","year":"2021","unstructured":"Shetty K.; Sherje A.P.; Nano intervention in topical delivery of corticosteroid for psoriasis and atopic dermatitis\u2014A systematic review. J Mater Sci Mater Med  2021,32(8),88","journal-title":"J Mater Sci Mater Med"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"e15364","DOI":"10.1111\/dth.15364","volume":"35","author":"Lis-\u015awi\u0119ty A.","year":"2022","unstructured":"Lis-\u015awi\u0119ty A.; Fr\u0105tczak A.; Proactive therapy: New perspectives for long\u2010term topical treatment of psoriasis. Dermatol Ther  2022,35(5),e15364","journal-title":"Dermatol Ther"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jaad.2017.09.074","volume":"78","author":"Yu S.H.","year":"2018","unstructured":"Yu S.H.; Drucker A.M.; Lebwohl M.; Silverberg J.I.; A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis. J Am Acad Dermatol  2018,78(4),733-740.e11","journal-title":"J Am Acad Dermatol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jaad.2018.03.040","volume":"79","author":"Gold L.S.","year":"2018","unstructured":"Gold L.S.; Lebwohl M.G.; Sugarman J.L.; Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials. J Am Acad Dermatol  2018,79(2),287-293","journal-title":"J Am Acad Dermatol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/0190-9622(92)70302-V","volume":"27","author":"Kragballe K.","year":"1992","unstructured":"Kragballe K.; Treatment of psoriasis with calcipotriol and other vitamin D analogues. J Am Acad Dermatol  1992,27(6),1001-1008","journal-title":"J Am Acad Dermatol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"8575","DOI":"10.3390\/ijms23158575","volume":"23","author":"Bro\u017cyna A.A.","year":"2022","unstructured":"Bro\u017cyna A.A.; Slominski R.M.; Nedoszytko B.; Zmijewski M.A.; Slominski A.T.; Vitamin D.; Vitamin D signaling in psoriasis: Pathogenesis and therapy. Int J Mol Sci  2022,23(15),8575","journal-title":"Int J Mol Sci"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/jcb.240490109","volume":"49","author":"Kragballe K.","year":"1992","unstructured":"Kragballe K.; Vitamin D analogues in the treatment of psoriasis. J Cell Biochem  1992,49(1),46-52","journal-title":"J Cell Biochem"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"4484","DOI":"10.3390\/jcm13154484","volume":"13","author":"Gisondi P.","year":"2024","unstructured":"Gisondi P.; Gracia-Caza\u00f1a T.; Kurzen H.; Galv\u00e1n J.; Calcipotriol\/Betamethasone dipropionate for the treatment of psoriasis: Mechanism of action and evidence of efficacy and safety versus topical corticosteroids. J Clin Med  2024,13(15),4484","journal-title":"J Clin Med"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"13313","DOI":"10.3390\/ijms241713313","volume":"24","author":"Lee H.J.","year":"2023","unstructured":"Lee H.J.; Kim M.; Challenges and future trends in the treatment of psoriasis. Int J Mol Sci  2023,24(17),13313","journal-title":"Int J Mol Sci"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/1523-1747.ep12294284","volume":"107","author":"Jinquan T.","year":"1996","unstructured":"Jinquan T.; Vorum H.; Larsen C.G.; Psoriasin: A novel chemotactic protein. J Invest Dermatol  1996,107(1),5-10","journal-title":"J Invest Dermatol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1080\/09546634.2017.1369494","volume":"29","author":"Sekhon S.","year":"2018","unstructured":"Sekhon S.; Jeon C.; Nakamura M.; Review of the mechanism of action of coal tar in psoriasis. J Dermatolog Treat  2018,29(3),230-232","journal-title":"J Dermatolog Treat"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"7488","DOI":"10.3390\/ijms21207488","volume":"21","author":"Tokuyama M.","year":"2020","unstructured":"Tokuyama M.; Mabuchi T.; New treatment addressing the pathogenesis of Psoriasis. Int J Mol Sci  2020,21(20),7488","journal-title":"Int J Mol Sci"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"adv00890","DOI":"10.2340\/actadv.v103.6525","volume":"103","author":"Amiri D.","year":"2023","unstructured":"Amiri D.; Schwarz C.W.; Gether L.; Skov L.; Safety and efficacy of topical calcineurin inhibitors in the treatment of facial and genital psoriasis: A systematic review. Acta Derm Venereol  2023,103,adv00890","journal-title":"Acta Derm Venereol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1080\/09546634.2017.1309349","volume":"28","author":"Khalil S.","year":"2017","unstructured":"Khalil S.; Bardawil T.; Stephan C.; Retinoids: A journey from the molecular structures and mechanisms of action to clinical uses in dermatology and adverse effects. J Dermatolog Treat  2017,28(8),684-696","journal-title":"J Dermatolog Treat"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.annder.2022.02.004","volume":"149","author":"Ariane M.","year":"2022","unstructured":"Ariane M.; Mah\u00e9 E.; Combined acitretin-methotrexate therapy seems safe and efficient in children with psoriasis. Ann Dermatol Venereol  2022,149(3),189-190","journal-title":"Ann Dermatol Venereol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/ijd.14349","volume":"58","author":"Chularojanamontri L.","year":"2019","unstructured":"Chularojanamontri L.; Silpa-archa N.; Wongpraparut C.; Limphoka P.; Long\u2010term safety and drug survival of acitretin in psoriasis: A retrospective observational study. Int J Dermatol  2019,58(5),593-599","journal-title":"Int J Dermatol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"426","DOI":"10.2340\/00015555-2599","volume":"97","author":"Raaby L.","year":"2017","unstructured":"Raaby L.; Zachariae C.; \u00d8stensen M.; Methotrexate use and monitoring in patients with psoriasis: A consensus report based on a danish expert meeting. Acta Derm Venereol  2017,97(4),426-432","journal-title":"Acta Derm Venereol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"e0153740","DOI":"10.1371\/journal.pone.0153740","volume":"11","author":"West J.","year":"2016","unstructured":"West J.; Ogston S.; Foerster J.; Safety and efficacy of methotrexate in Psoriasis: A meta-analysis of published trials. PLoS One  2016,11(5),e0153740","journal-title":"PLoS One"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/1744666X.2021.1886081","volume":"17","author":"Iznardo H.","year":"2021","unstructured":"Iznardo H.; Puig L.; The interleukin-1 family cytokines in psoriasis: Pathogenetic role and therapeutic perspectives. Expert Rev Clin Immunol  2021,17(2),187-199","journal-title":"Expert Rev Clin Immunol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jid.2018.07.025","volume":"139","author":"Cai Y.","year":"2019","unstructured":"Cai Y.; Xue F.; Quan C.; A critical role of the IL-1\u03b2\u2013IL-1R signaling pathway in skin inflammation and psoriasis pathogenesis. J Invest Dermatol  2019,139(1),146-156","journal-title":"J Invest Dermatol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.jid.2020.07.012","volume":"141","author":"Verma D.","year":"2021","unstructured":"Verma D.; Fekri S.Z.; Sigurdardottir G.; Bivik Eding C.; Sandin C.; Enerb\u00e4ck C.; Enhanced inflammasome activity in patients with psoriasis promotes systemic inflammation. J Invest Dermatol  2021,141(3),586-595.e5","journal-title":"J Invest Dermatol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/bjd.13614","volume":"173","author":"Mansouri B.","year":"2015","unstructured":"Mansouri B.; Richards L.; Menter A.; Treatment of two patients with generalized pustular psoriasis with the interleukin-1\u03b2 inhibitor gevokizumab. Br J Dermatol  2015,173(1),239-241","journal-title":"Br J Dermatol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S1074-7613(00)00070-4","volume":"13","author":"Oppmann B.","year":"2000","unstructured":"Oppmann B.; Lesley R.; Blom B.; Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity  2000,13(5),715-725","journal-title":"Immunity"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.3390\/cells9092044","volume":"9","author":"Pastor-Fern\u00e1ndez G.","year":"2020","unstructured":"Pastor-Fern\u00e1ndez G.; Mariblanca I.R.; Navarro M.N.; Decoding IL-23 signaling cascade for new therapeutic opportunities. Cells  2020,9(9),2044","journal-title":"Cells"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"e0220868","DOI":"10.1371\/journal.pone.0220868","volume":"14","author":"Sawyer L.M.","year":"2019","unstructured":"Sawyer L.M.; Malottki K.; Sabry-Grant C.; Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. PLoS One  2019,14(8),e0220868","journal-title":"PLoS One"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1111\/jdv.16521","volume":"34","author":"Strober B.","year":"2020","unstructured":"Strober B.; Menter A.; Leonardi C.; Efficacy of risankizumab in patients with moderate\u2010to\u2010severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: An integrated analysis of the phase III UltIMMa\u20101 and UltIMMa\u20102 studies. J Eur Acad Dermatol Venereol  2020,34(12),2830-2838","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/jdv.16073","volume":"34","author":"Loft N.D.","year":"2020","unstructured":"Loft N.D.; Vaengebjerg S.; Halling A.S.; Skov L.; Egeberg A.; Adverse events with IL\u201017 and IL\u201023 inhibitors for psoriasis and psoriatic arthritis: A systematic review and meta\u2010analysis of phase III studies. J Eur Acad Dermatol Venereol  2020,34(6),1151-1160","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","volume":"8","author":"Feagan B.G.","year":"2023","unstructured":"Feagan B.G.; Sands B.E.; Sandborn W.J.; Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): A randomised, double-blind, controlled, phase 2, proof-of-concept trial. Lancet Gastroenterol Hepatol  2023,8(4),307-320","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.3390\/ijms20133318","volume":"20","author":"Madonna S.","year":"2019","unstructured":"Madonna S.; Girolomoni G.; Dinarello C.A.; Albanesi C.; The significance of IL-36 hyperactivation and IL-36R targeting in psoriasis. Int J Mol Sci  2019,20(13),3318","journal-title":"Int J Mol Sci"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/exd.13841","volume":"28","author":"Su Z.","year":"2019","unstructured":"Su Z.; Paulsboe S.; Wetter J.; IL \u201036 receptor antagonistic antibodies inhibit inflammatory responses in preclinical models of psoriasiform dermatitis. Exp Dermatol  2019,28(2),113-120","journal-title":"Exp Dermatol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"9089","DOI":"10.1038\/s41598-019-45626-w","volume":"9","author":"Todorovi\u0107 V.","year":"2019","unstructured":"Todorovi\u0107 V.; Su Z.; Putman C.B.; Small molecule IL-36\u03b3 antagonist as a novel therapeutic approach for plaque psoriasis. Sci Rep  2019,9(1),9089","journal-title":"Sci Rep"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.3390\/ijms22094344","volume":"22","author":"Iznardo H.","year":"2021","unstructured":"Iznardo H.; Puig L.; Exploring the role of IL-36 cytokines as a new target in psoriatic disease. Int J Mol Sci  2021,22(9),4344","journal-title":"Int J Mol Sci"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"Armstrong A.W.","year":"2020","unstructured":"Armstrong A.W.; Read C.; Pathophysiology, clinical presentation, and treatment of psoriasis. JAMA  2020,323(19),1945-1960","journal-title":"JAMA"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","volume":"151","author":"Kalb R.E.","year":"2015","unstructured":"Kalb R.E.; Fiorentino D.F.; Lebwohl M.G.; Risk of serious infection with biologic and systemic treatment of psoriasis. JAMA Dermatol  2015,151(9),961-969","journal-title":"JAMA Dermatol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ejpb.2022.05.012","volume":"176","author":"Mascarenhas-Melo F.","year":"2022","unstructured":"Mascarenhas-Melo F.; Carvalho A.; Gon\u00e7alves M.B.S.; Paiva-Santos A.C.; Veiga F.; Nanocarriers for the topical treatment of psoriasis - Pathophysiology, conventional treatments, nanotechnology, regulatory and toxicology. Eur J Pharm Biopharm  2022,176,95-107","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.biopha.2018.06.136","volume":"106","author":"Rapalli V.K.","year":"2018","unstructured":"Rapalli V.K.; Singhvi G.; Dubey S.K.; Gupta G.; Chellappan D.K.; Dua K.; Emerging landscape in psoriasis management: From topical application to targeting biomolecules. Biomed Pharmacother  2018,106,707-713","journal-title":"Biomed Pharmacother"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jaci.2016.03.048","volume":"138","author":"Fujiyama T.","year":"2016","unstructured":"Fujiyama T.; Ito T.; Umayahara T.; Topical application of a vitamin D3 analogue and corticosteroid to psoriasis plaques decreases skin infiltration of TH17 cells and their ex vivo expansion. J Allergy Clin Immunol  2016,138(2),517-528.e5","journal-title":"J Allergy Clin Immunol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-020-01261-8","volume":"80","author":"Nogueira M.","year":"2020","unstructured":"Nogueira M.; Puig L.; Torres T.; JAK inhibitors for treatment of Psoriasis: Focus on selective TYK2 inhibitors. Drugs  2020,80(4),341-352","journal-title":"Drugs"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s13075-021-02509-8","volume":"23","author":"Hawerkamp H.C.","year":"2021","unstructured":"Hawerkamp H.C.; Domdey A.; Radau L.; Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activation. Arthritis Res Ther  2021,23(1),144","journal-title":"Arthritis Res Ther"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"175276","DOI":"10.1016\/j.ejphar.2022.175276","volume":"933","author":"Tang J.","year":"2022","unstructured":"Tang J.; Liu C.; Liu S.; Inhibition of JAK1\/STAT3 pathway by 2-methoxyestradiol ameliorates psoriatic features in vitro and in an imiquimod-induced psoriasis-like mouse model. Eur J Pharmacol  2022,933,175276","journal-title":"Eur J Pharmacol"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"15438","DOI":"10.1021\/acs.jmedchem.4c01055","volume":"67","author":"Chen L.","year":"2024","unstructured":"Chen L.; Wang L.; Gao J.; Design, synthesis, and biological activity of novel quinone derivatives as potent STAT3 inhibitors for psoriasis treatment. J Med Chem  2024,67(17),15438-15455","journal-title":"J Med Chem"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jaad.2018.04.018","volume":"79","author":"Hosking A.M.","year":"2018","unstructured":"Hosking A.M.; Juhasz M.; Mesinkovska N.A.; Topical Janus kinase inhibitors: A review of applications in dermatology. J Am Acad Dermatol  2018,79(3),535-544","journal-title":"J Am Acad Dermatol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/bjd.14493","volume":"175","author":"Papp K.A.","year":"2016","unstructured":"Papp K.A.; Reich K.; Paul C.; A prospective phase III, randomized, double\u2010blind, placebo\u2010controlled study of brodalumab in patients with moderate\u2010to\u2010severe plaque psoriasis. Br J Dermatol  2016,175(2),273-286","journal-title":"Br J Dermatol"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/jid.2010.255","volume":"131","author":"Miyoshi K.","year":"2011","unstructured":"Miyoshi K.; Takaishi M.; Nakajima K.; Stat3 as a therapeutic target for the treatment of psoriasis: A clinical feasibility study with STA-21, a Stat3 inhibitor. J Invest Dermatol  2011,131(1),108-117","journal-title":"J Invest Dermatol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"111344","DOI":"10.1016\/j.intimp.2023.111344","volume":"127","author":"Ti C.","year":"2024","unstructured":"Ti C.; Chen H.; Zhou W.; WB518, a novel STAT3 inhibitor, effectively alleviates IMQ and TPA-induced animal psoriasis by inhibiting STAT3 phosphorylation and Keratin 17. Int Immunopharmacol  2024,127,111344","journal-title":"Int Immunopharmacol"},{"key":"ref=126","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/ng.694","volume":"42","year":"2010","unstructured":"A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet  2010,42(11),985-990","journal-title":"Nat Genet"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"5373","DOI":"10.2147\/JIR.S380686","volume":"15","author":"Shang L.","year":"2022","unstructured":"Shang L.; Cao J.; Zhao S.; Zhang J.; He Y.; TYK2 in immune responses and treatment of Psoriasis. J Inflamm Res  2022,15,5373-5385","journal-title":"J Inflamm Res"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","volume":"379","author":"Papp K.","year":"2018","unstructured":"Papp K.; Gordon K.; Tha\u00e7i D.; Phase 2 trial of selective tyrosine Kinase 2 inhibition in Psoriasis. N Engl J Med  2018,379(14),1313-1321","journal-title":"N Engl J Med"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/j.jid.2019.11.027","volume":"140","author":"Page K.M.","year":"2020","unstructured":"Page K.M.; Suarez-Farinas M.; Suprun M.; Molecular and cellular responses to the TYK2\/JAK1 inhibitor PF-06700841 reveal reduction of skin inflammation in Plaque Psoriasis. J Invest Dermatol  2020,140(8),1546-1555.e4","journal-title":"J Invest Dermatol"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.3389\/fimmu.2019.02847","volume":"10","author":"Solimani F.","year":"2019","unstructured":"Solimani F.; Meier K.; Ghoreschi K.; Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol  2019,10,2847","journal-title":"Front Immunol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1016\/j.jid.2020.03.962","volume":"140","author":"Forman S.B.","year":"2020","unstructured":"Forman S.B.; Pariser D.M.; Poulin Y.; TYK2\/JAK1 inhibitor PF-06700841 in patients with plaque Psoriasis: Phase IIa, randomized, double-blind, placebo-controlled trial. J Invest Dermatol  2020,140(12),2359-2370.e5","journal-title":"J Invest Dermatol"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamadermatol.2024.2701","volume":"160","author":"Armstrong A.W.","year":"2024","unstructured":"Armstrong A.W.; Gooderham M.; Lynde C.; Tyrosine kinase 2 inhibition with Zasocitinib (TAK-279) in Psoriasis. JAMA Dermatol  2024,160(10),1066-1074","journal-title":"JAMA Dermatol"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1177\/10600280231153863","volume":"58","author":"Truong T.M.","year":"2024","unstructured":"Truong T.M.; Pathak G.N.; Singal A.; Taranto V.; Rao B.K.; Deucravacitinib: The first FDA-approved oral TYK2 inhibitor for moderate to severe plaque Psoriasis. Ann Pharmacother  2024,58(4),416-427","journal-title":"Ann Pharmacother"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"712313","DOI":"10.3389\/fmed.2022.712313","volume":"9","author":"Thakur V.","year":"2022","unstructured":"Thakur V.; Mahajan R.; Novel therapeutic target(s) for psoriatic disease. Front Med  2022,9,712313","journal-title":"Front Med"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.bcp.2018.02.031","volume":"151","author":"Schiering C.","year":"2018","unstructured":"Schiering C.; Vonk A.; Das S.; Stockinger B.; Wincent E.; Cytochrome P4501-inhibiting chemicals amplify aryl hydrocarbon receptor activation and IL-22 production in T helper 17 cells. Biochem Pharmacol  2018,151,47-58","journal-title":"Biochem Pharmacol"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1016\/j.jid.2017.05.004","volume":"137","author":"Smith S.H.","year":"2017","unstructured":"Smith S.H.; Jayawickreme C.; Rickard D.J.; Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans. J Invest Dermatol  2017,137(10),2110-2119","journal-title":"J Invest Dermatol"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2014.04.019","volume":"40","author":"Di Meglio P.","year":"2014","unstructured":"Di Meglio P.; Duarte J.H.; Ahlfors H.; Activation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditions. Immunity  2014,40(6),989-1001","journal-title":"Immunity"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.jaad.2020.10.085","volume":"84","author":"Bissonnette R.","year":"2021","unstructured":"Bissonnette R.; Stein Gold L.; Rubenstein D.S.; Tallman A.M.; Armstrong A.; Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor\u2013modulating agent. J Am Acad Dermatol  2021,84(4),1059-1067","journal-title":"J Am Acad Dermatol"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.3389\/fimmu.2018.01210","volume":"9","author":"Tang L.","year":"2018","unstructured":"Tang L.; Yang X.; Liang Y.; Xie H.; Dai Z.; Zheng G.; Transcription factor retinoid-related orphan receptor \u03b3t: A promising target for the treatment of psoriasis. Front Immunol  2018,9,1210","journal-title":"Front Immunol"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"10976","DOI":"10.1021\/acs.jmedchem.8b00588","volume":"61","author":"Pandya V.B.","year":"2018","unstructured":"Pandya V.B.; Kumar S.; Sachchidanand, Sharma R, Desai RC. Combating autoimmune diseases with retinoic acid receptor-related orphan receptor-\u03b3 (ROR\u03b3 or RORc) inhibitors: Hits and misses. J Med Chem  2018,61(24),10976-10995","journal-title":"J Med Chem"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1080\/13543784.2016.1187130","volume":"25","author":"Torres T.","year":"2016","unstructured":"Torres T.; Romanelli M.; Chiricozzi A.; A revolutionary therapeutic approach for psoriasis: Bispecific biological agents. Expert Opin Investig Drugs  2016,25(7),751-754","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1016\/j.cellsig.2014.05.014","volume":"26","author":"Schafer P.H.","year":"2014","unstructured":"Schafer P.H.; Parton A.; Capone L.; Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal  2014,26(9),2016-2029","journal-title":"Cell Signal"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3899\/jrheum.150639","volume":"93","author":"Marchesoni A.","year":"2015","unstructured":"Marchesoni A.; Lubrano E.; Cauli A.; Ricci M.; Manara M.; Psoriatic disease: Update on traditional disease-modifying antirheumatic drugs. J Rheumatol Suppl  2015,93(0),61-64","journal-title":"J Rheumatol Suppl"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"402","DOI":"10.18553\/jmcp.2010.16.6.402","volume":"16","author":"Schafer J.A.","year":"2010","unstructured":"Schafer J.A.; Kjesbo N.K.; Gleason P.P.; Formulary review of 2 new biologic agents: Tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis. J Manag Care Pharm  2010,16(6),402-416","journal-title":"J Manag Care Pharm"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12944-016-0178-7","volume":"15","author":"Borodzicz S.","year":"2016","unstructured":"Borodzicz S.; Rudnicka L.; Mirowska-Guzel D.; Cudnoch-Jedrzejewska A.; The role of epidermal sphingolipids in dermatologic diseases. Lipids Health Dis  2016,15(1),13","journal-title":"Lipids Health Dis"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/nrd4099","volume":"12","author":"Kunkel G.T.","year":"2013","unstructured":"Kunkel G.T.; Maceyka M.; Milstien S.; Spiegel S.; Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov  2013,12(9),688-702","journal-title":"Nat Rev Drug Discov"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jdermsci.2017.11.003","volume":"89","author":"Krause A.","year":"2018","unstructured":"Krause A.; D\u2019Ambrosio D.; Dingemanse J.; Modeling clinical efficacy of the S1P receptor modulator ponesimod in psoriasis. J Dermatol Sci  2018,89(2),136-145","journal-title":"J Dermatol Sci"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jdermsci.2021.04.004","volume":"102","author":"Okura I.","year":"2021","unstructured":"Okura I.; Kamata M.; Asano Y.; Fingolimod ameliorates imiquimod-induced psoriasiform dermatitis by sequestrating interleukin-17-producing? d T cells in secondary lymph nodes. J Dermatol Sci  2021,102(2),116-125","journal-title":"J Dermatol Sci"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1016\/S0140-6736(14)60803-5","volume":"384","author":"Vaclavkova A.","year":"2014","unstructured":"Vaclavkova A.; Chimenti S.; Arenberger P.; Oral ponesimod in patients with chronic plaque psoriasis: A randomised, double-blind, placebo-controlled phase 2 trial. Lancet  2014,384(9959),2036-2045","journal-title":"Lancet"},{"key":"ref=150","first-page":"521","volume":"113","author":"Chew WS","year":"2016","unstructured":"Chew WS; Wang W; Herr DR; To fingolimod and beyond: The rich pipeline of drug candidates that target S1P signaling. Pharma col Res  2016,113(Pt A),521-532","journal-title":"Pharma col Res"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1124\/jpet.110.176487","volume":"337","author":"Piali L.","year":"2011","unstructured":"Piali L.; Froidevaux S.; Hess P.; The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther  2011,337(2),547-556","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/j.1365-4632.2004.02195.x","volume":"43","author":"Huang J.","year":"2004","unstructured":"Huang J.; Li G.; Xiang J.; Yin D.; Chi R.; Immunohistochemical study of serotonin in lesions of psoriasis. Int J Dermatol  2004,43(6),408-411","journal-title":"Int J Dermatol"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/354957","volume":"2015","author":"Arreola R.","year":"2015","unstructured":"Arreola R.; Becerril-Villanueva E.; Cruz-Fuentes C.; Immunomodulatory effects mediated by serotonin. J Immunol Res  2015,2015,1-21","journal-title":"J Immunol Res"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1007\/s12035-020-01889-3","volume":"57","author":"Martins A.M.","year":"2020","unstructured":"Martins A.M.; Ascenso A.; Ribeiro H.M.; Marto J.; Current and future therapies for psoriasis with a focus on serotonergic drugs. Mol Neurobiol  2020,57(5),2391-2419","journal-title":"Mol Neurobiol"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/joim.12093","volume":"274","author":"Thorslund K.","year":"2013","unstructured":"Thorslund K.; Svensson T.; Nordlind K.; Ekbom A.; Fored C.M.; Use of serotonin reuptake inhibitors in patients with psoriasis is associated with a decreased need for systemic psoriasis treatment: A population\u2010based cohort study. J Intern Med  2013,274(3),281-287","journal-title":"J Intern Med"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/cpt.1852","volume":"108","author":"Weisel K.","year":"2020","unstructured":"Weisel K.; Berger S.; Papp K.; Response to inhibition of receptor\u2010interacting protein kinase 1 (RIPK1) in active Plaque Psoriasis: A randomized placebo\u2010controlled study. Clin Pharmacol Ther  2020,108(4),808-816","journal-title":"Clin Pharmacol Ther"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41419-020-2328-0","volume":"11","author":"Duan X.","year":"2020","unstructured":"Duan X.; Liu X.; Liu N.; Inhibition of keratinocyte necroptosis mediated by RIPK1\/RIPK3\/MLKL provides a protective effect against psoriatic inflammation. Cell Death Dis  2020,11(2),134","journal-title":"Cell Death Dis"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jdermsci.2018.04.007","volume":"91","author":"Saito N.","year":"2018","unstructured":"Saito N.; Honma M.; Shibuya T.; RIPK1 downregulation in keratinocyte enhances TRAIL signaling in psoriasis. J Dermatol Sci  2018,91(1),79-86","journal-title":"J Dermatol Sci"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"3680","DOI":"10.3390\/molecules27123680","volume":"27","author":"Fishman P.","year":"2022","unstructured":"Fishman P.; Drugs targeting the A3 adenosine receptor: Human clinical study data. Molecules  2022,27(12),3680","journal-title":"Molecules"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"105731","DOI":"10.1016\/j.phrs.2021.105731","volume":"170","author":"L\u00f3pez-Cano M.","year":"2021","unstructured":"L\u00f3pez-Cano M.; Filgaira I.; Nolen E.G.; Optical control of adenosine A3 receptor function in psoriasis. Pharmacol Res  2021,170,105731","journal-title":"Pharmacol Res"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/2310970","volume":"2018","author":"Cohen S.","year":"2018","unstructured":"Cohen S.; Barer F.; Itzhak I.; Silverman M.H.; Fishman P.; Inhibition of IL-17 and IL-23 in human Keratinocytes by the A 3 Adenosine receptor Agonist Piclidenoson. J Immunol Res  2018,2018,1-8","journal-title":"J Immunol Res"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.4049\/jimmunol.1801519","volume":"202","author":"Campbell J.J.","year":"2019","unstructured":"Campbell J.J.; Ebsworth K.; Ertl L.S.; Efficacy of chemokine receptor inhibition in treating IL-36\u03b1\u2013induced Psoriasiform inflammation. J Immunol  2019,202(6),1687-1692","journal-title":"J Immunol"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3390\/ijms25021005","volume":"25","author":"Liu W.","year":"2024","unstructured":"Liu W.; The involvement of cysteine-X-cysteine motif chemokine receptors in skin homeostasis and the pathogenesis of allergic contact dermatitis and Psoriasis. Int J Mol Sci  2024,25(2),1005","journal-title":"Int J Mol Sci"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1046\/j.1523-1747.1998.00074.x","volume":"110","author":"Kulke R.","year":"1998","unstructured":"Kulke R.; Bornscheuer E.; Schl\u00fcter C.; The CXC receptor 2 is overexpressed in psoriatic epidermis. J Invest Dermatol  1998,110(1),90-94","journal-title":"J Invest Dermatol"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1189\/jlb.0408231","volume":"84","author":"Bento A.F.","year":"2008","unstructured":"Bento A.F.; Leite D.F.P.; Claudino R.F.; Hara D.B.; Leal P.C.; Calixto J.B.; The selective nonpeptide CXCR2 antagonist SB225002 ameliorates acute experimental colitis in mice. J Leukoc Biol  2008,84(4),1213-1221","journal-title":"J Leukoc Biol"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00403-018-1879-8","volume":"311","author":"Zhang M.","year":"2019","unstructured":"Zhang M.; Zhang X.; The role of PI3K\/AKT\/FOXO signaling in psoriasis. Arch Dermatol Res  2019,311(2),83-91","journal-title":"Arch Dermatol Res"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1080\/09546634.2018.1466022","volume":"29","author":"Wu J.J.","year":"2018","unstructured":"Wu J.J.; Feldman S.R.; Rastogi S.; Menges B.; Lingohr-Smith M.; Lin J.; Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States. J Dermatolog Treat  2018,29(8),769-774","journal-title":"J Dermatolog Treat"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"150","DOI":"10.31138\/mjr.33.1.150","volume":"33","author":"Gialouri C.G.","year":"2022","unstructured":"Gialouri C.G.; Evangelatos G.; Fragoulis G.E.; Choosing the appropriate target for the treatment of psoriatic arthritis: TNF\u03b1, IL-17, IL-23 or JAK inhibitors? Mediterr J Rheumatol  2022,33(Suppl. 1),150-161","journal-title":"Mediterr J Rheumatol"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.bbrc.2019.09.010","volume":"519","author":"Abe S.","year":"2019","unstructured":"Abe S.; Yuasa K.; Sudachitin, a polymethoxyflavone from Citrus sudachi, induces apoptosis via the regulation of MAPK pathways in human keratinocyte HaCaT cells. Biochem Biophys Res Commun  2019,519(2),344-350","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.jaci.2019.06.019","volume":"144","author":"Sakurai K.","year":"2019","unstructured":"Sakurai K.; Dainichi T.; Garcet S.; Cutaneous p38 mitogen-activated protein kinase activation triggers psoriatic dermatitis. J Allergy Clin Immunol  2019,144(4),1036-1049","journal-title":"J Allergy Clin Immunol"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jid.2018.07.032","volume":"139","author":"Liang J.","year":"2019","unstructured":"Liang J.; Chen P.; Li C.; IL-22 down-regulates Cx43 expression and decreases gap junctional intercellular communication by activating the JNK pathway in psoriasis. J Invest Dermatol  2019,139(2),400-411","journal-title":"J Invest Dermatol"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.intimp.2018.11.031","volume":"66","author":"Huang X.","year":"2019","unstructured":"Huang X.; Yu P.; Liu M.; ERK inhibitor JSI287 alleviates imiquimod-induced mice skin lesions by ERK\/IL-17 signaling pathway. Int Immunopharmacol  2019,66,236-241","journal-title":"Int Immunopharmacol"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13075-022-02850-6","volume":"24","author":"Gaur R.","year":"2022","unstructured":"Gaur R.; Mensah K.A.; Stricker J.; CC-99677, a novel, oral, selective covalent MK2 inhibitor, sustainably reduces pro-inflammatory cytokine production. Arthritis Res Ther  2022,24(1),199","journal-title":"Arthritis Res Ther"},{"key":"ref=174","first-page":"42","volume":"15","author":"El-Esawy F.M.","year":"2022","unstructured":"El-Esawy F.M.; Ahmed I.A.; El-Fallah A.A.; Salem R.M.; Methotrexate mechanism of action in plaque Psoriasis: Something new in the old view. J Clin Aesthet Dermatol  2022,15(8),42-46","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"805705","DOI":"10.1155\/2013\/805705","volume":"2013","author":"Colombo M.D.","year":"2013","unstructured":"Colombo M.D.; Cassano N.; Bellia G.; Vena G.A.; Cyclosporine regimens in plaque psoriasis: An overview with special emphasis on dose, duration, and old and new treatment approaches. ScientificWorldJournal  2013,2013(1),805705","journal-title":"ScientificWorldJournal"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","volume":"88","author":"Armstrong A.W.","year":"2023","unstructured":"Armstrong A.W.; Gooderham M.; Warren R.B.; Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol  2023,88(1),29-39","journal-title":"J Am Acad Dermatol"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/sj.jidsymp.5650037","volume":"12","author":"Tan J.K.","year":"2007","unstructured":"Tan J.K.; Aphale A.; Malaviya R.; Sun Y.; Gottlieb A.B.; Mechanisms of action of etanercept in psoriasis. J Investig Dermatol Symp Proc  2007,12(1),38-45","journal-title":"J Investig Dermatol Symp Proc"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","volume":"9","author":"Li H.","year":"2018","unstructured":"Li H.; Zuo J.; Tang W.; Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. Front Pharmacol  2018,9,1048","journal-title":"Front Pharmacol"},{"key":"ref=179","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/jdv.17026","volume":"35","author":"Lebwohl M.","year":"2021","unstructured":"Lebwohl M.; Warren R.B.; Editorial: Fixed-dose combination calcipotriol\/betamethasone dipropionate foam in the treatment of patients with psoriasis. J Eur Acad Dermatol Venereol  2021,35(Suppl. 1),3-4","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=180","first-page":"585","volume":"20","author":"Ortonne J.P.","year":"2010","unstructured":"Ortonne J.P.; Noerrelund K.L.; Papp K.; Comparison of two different dose combinations of calcipotriol\/hydrocortisone ointment used once daily for the treatment of psoriasis vulgaris on the face and body. Eur J Dermatol  2010,20(5),585-589","journal-title":"Eur J Dermatol"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1001\/archderm.1959.01560150092014","volume":"79","author":"Greenlee M.R.","year":"1959","unstructured":"Greenlee M.R.; Epstein W.L.; Triamcinolone in the treatment of psoriasis. Arch Dermatol  1959,79(3),350-351","journal-title":"Arch Dermatol"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jdermsci.2015.06.016","volume":"80","author":"Mizuno K.","year":"2015","unstructured":"Mizuno K.; Morizane S.; Takiguchi T.; Iwatsuki K.; Dexamethasone but not tacrolimus suppresses TNF-\u03b1-induced thymic stromal lymphopoietin expression in lesional keratinocytes of atopic dermatitis model. J Dermatol Sci  2015,80(1),45-53","journal-title":"J Dermatol Sci"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1634\/theoncologist.2012-0219","volume":"18","author":"Brooks M.B.","year":"2013","unstructured":"Brooks M.B.; Erlotinib and gefitinib, epidermal growth factor receptor kinase inhibitors, may treat non-cancer-related tumor necrosis factor-\u03b1 mediated inflammatory diseases. Oncologist  2013,18(1),e3-e5","journal-title":"Oncologist"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"247","DOI":"10.36849\/JDD.7399","volume":"22","author":"Kircik L.","year":"2023","unstructured":"Kircik L.; Bhatia N.; Lain E.; Jacobson A.; Breaking the frustrating cycle of topical steroids in psoriasis: a review of a novel vehicle for fixed-dose combination Halobetasol Propionate\/Tazarotene. J Drugs Dermatol  2023,22(3),247-251","journal-title":"J Drugs Dermatol"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1111\/j.1365-2133.2005.06661.x","volume":"152","author":"Gottlieb A.B.","year":"2005","unstructured":"Gottlieb A.B.; Griffiths C.E.M.; Ho V.C.; Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: A double-blind, multicentre, randomized, dose-finding trial. Br J Dermatol  2005,152(6),1219-1227","journal-title":"Br J Dermatol"},{"key":"ref=186","first-page":"505","volume":"5","author":"Rivard J.","year":"2006","unstructured":"Rivard J.; Janiga J.; Lim H.W.; Tacrolimus ointment 0.1% alone and in combination with medium-dose UVA1 in the treatment of palmar or plantar psoriasis. J Drugs Dermatol  2006,5(6),505-510","journal-title":"J Drugs Dermatol"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2165\/00128071-200405020-00001","volume":"5","author":"Guenther L.C.","year":"2004","unstructured":"Guenther L.C.; Fixed-dose combination therapy for psoriasis. Am J Clin Dermatol  2004,5(2),71-77","journal-title":"Am J Clin Dermatol"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/S0190-9622(94)70118-0","volume":"30","author":"Sips A.J.A.M.","year":"1994","unstructured":"Sips A.J.A.M.; Netelenbos J.C.; Barto R.; Verburgh C.A.; Nieboer C.; van der Vijgh W.J.F.; Topically applied low-dose calcitriol has no calciotropic effect in patients with stable plaque psoriasis. J Am Acad Dermatol  1994,30(6),966-969","journal-title":"J Am Acad Dermatol"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/j.1346-8138.2006.00022.x","volume":"33","author":"Abe M.","year":"2006","unstructured":"Abe M.; Syuto T.; Hasegawa M.; Sogabe Y.; Yokoyama Y.; Ishikawa O.; Daily versus intermittent application of high\u2010concentration tacalcitol ointment in combination with low\u2010dose cyclosporin for psoriasis vulgaris. J Dermatol  2006,33(2),108-111","journal-title":"J Dermatol"},{"key":"ref=190","first-page":"657","volume":"139","author":"Senter T.P.","year":"1983","unstructured":"Senter T.P.; Stimson D.H.; Charles G.; Brand R.J.; Comparison of two therapeutic regimens using the same topical corticoid for stable psoriasis. West J Med  1983,139(5),657-662","journal-title":"West J Med"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"Mease P.","year":"2017","unstructured":"Mease P.; Hall S.; FitzGerald O.; Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. N Engl J Med  2017,377(16),1537-1550","journal-title":"N Engl J Med"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1517\/14656566.6.10.1735","volume":"6","author":"Reid D.C.","year":"2005","unstructured":"Reid D.C.; Kimball A.B.; Clobetasol propionate foam in the treatment of psoriasis. Expert Opin Pharmacother  2005,6(10),1735-1740","journal-title":"Expert Opin Pharmacother"},{"key":"ref=193","first-page":"92","volume":"105","author":"Bagel J.","year":"2020","unstructured":"Bagel J.; Thibodeaux Q.G.; Han G.; Halobetasol propionate for the management of psoriasis. Cutis  2020,105(2),92-96","journal-title":"Cutis"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/S0140-6736(83)92607-7","volume":"321","author":"H\u00f6nigsmann H.","year":"1983","unstructured":"H\u00f6nigsmann H.; Wolff K.; Isotretinoin-PUVA for psoriasis. Lancet  1983,321(8318),236","journal-title":"Lancet"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/clpt.1985.68","volume":"37","author":"Massarella J.","year":"1985","unstructured":"Massarella J.; Vane F.; Bugg\u00e9 C.; Etretinate kinetics during chronic dosing in severe psoriasis. Clin Pharmacol Ther  1985,37(4),439-446","journal-title":"Clin Pharmacol Ther"},{"key":"ref=196","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s13555-020-00364-0","volume":"10","year":"2020","unstructured":"Reddy Vidhatha Psoriasis Vulgaris successfully treated with goeckerman treatment at home: A patient and Physician\u2019s experience. Dermatol Ther  2020,10(3),329-338","journal-title":"Dermatol Ther"},{"key":"ref=197","first-page":"676","volume":"30","author":"Parish L.C.","year":"1982","unstructured":"Parish L.C.; Hertz J.J.; Oxipor VHC lotion versus Tegrin in the treatment of psoriasis. Cutis  1982,30(5),676-678","journal-title":"Cutis"},{"key":"ref=198","first-page":"1258","volume":"9","author":"Slutsky J.B.","year":"2010","unstructured":"Slutsky J.B.; Clark R.A.F.; Remedios A.A.; Klein P.A.; An evidence-based review of the efficacy of coal tar preparations in the treatment of psoriasis and atopic dermatitis. J Drugs Dermatol  2010,9(10),1258-1264","journal-title":"J Drugs Dermatol"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S0190-9622(83)70069-1","volume":"8","author":"Kulick K.B.","year":"1983","unstructured":"Kulick K.B.; Mogavero H.; Provost T.T.; Reichlin M.; Serologic studies in patients with lupus erythematosus and psoriasis. J Am Acad Dermatol  1983,8(5),631-634","journal-title":"J Am Acad Dermatol"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/jdv.18812","volume":"37","author":"Warren R.B.","year":"2023","unstructured":"Warren R.B.; Strober B.; Silverberg J.I.; Oral orismilast: Efficacy and safety in moderate\u2010to\u2010severe psoriasis and development of modified release tablets. J Eur Acad Dermatol Venereol  2023,37(4),711-720","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"115195","DOI":"10.1016\/j.ejmech.2023.115195","volume":"250","author":"Li G.","year":"2023","unstructured":"Li G.; He D.; Cai X.; Advances in the development of phosphodiesterase-4 inhibitors. Eur J Med Chem  2023,250,115195","journal-title":"Eur J Med Chem"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.2147\/JIR.S356316","volume":"15","author":"Zhang J.","year":"2022","unstructured":"Zhang J.; Qi F.; Dong J.; Tan Y.; Gao L.; Liu F.; Application of Baricitinib in Dermatology. J Inflamm Res  2022,15,1935-1941","journal-title":"J Inflamm Res"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1007\/s13555-022-00840-9","volume":"12","author":"Drakos A.","year":"2022","unstructured":"Drakos A.; Vender R.; A review of the clinical trial landscape in Psoriasis: An update for clinicians. Dermatol Ther  2022,12(12),2715-2730","journal-title":"Dermatol Ther"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s13555-022-00878-9","volume":"13","author":"Martin G.","year":"2023","unstructured":"Martin G.; Novel therapies in plaque psoriasis: A review of tyrosine kinase 2 inhibitors. Dermatol Ther  2023,13(2),417-435","journal-title":"Dermatol Ther"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"176202","DOI":"10.1016\/j.ejphar.2023.176202","volume":"962","author":"Kubota-Ishida N.","year":"2024","unstructured":"Kubota-Ishida N.; Kaji C.; Matsumoto S.; ME3183, a novel phosphodiesterase-4 inhibitor, exhibits potent anti-inflammatory effects and is well tolerated in a non-clinical study. Eur J Pharmacol  2024,962,176202","journal-title":"Eur J Pharmacol"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1080\/14656566.2024.2373354","volume":"25","author":"Portarapillo A.","year":"2024","unstructured":"Portarapillo A.; Potestio L.; Tommasino N.; Novel pharmacotherapies and breakthroughs in psoriasis treatment: 2024 and beyond. Expert Opin Pharmacother  2024,25(9),1187-1198","journal-title":"Expert Opin Pharmacother"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/psp4.12948","volume":"12","author":"Ooi Q.X.","year":"2023","unstructured":"Ooi Q.X.; Kristoffersson A.; Korell J.; Flack M.L.; Plan E.; Weber B.; Bounded integer model-based analysis of psoriasis area and severity index in patients with moderate-to-severe plaque psoriasis receiving BI 730357. CPT Pharmacometrics Syst Pharmacol  2023,12(6),758-769","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"ref=208","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13543776.2017.1262350","volume":"27","author":"Gege C.","year":"2017","unstructured":"Gege C.; ROR\u03b3t inhibitors as potential back-ups for the phase II candidate VTP-43742 from Vitae Pharmaceuticals: Patent evaluation of WO2016061160 and US20160122345. Expert Opin Ther Pat  2017,27(1),1-8","journal-title":"Expert Opin Ther Pat"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"4983","DOI":"10.3390\/ijms22094983","volume":"22","author":"Petit R.G.","year":"2021","unstructured":"Petit R.G.; Cano A.; Ortiz A.; Psoriasis: From pathogenesis to pharmacological and nano-technological-based therapeutics. Int J Mol Sci  2021,22(9),4983","journal-title":"Int J Mol Sci"},{"key":"ref=210","first-page":"55","volume":"14","author":"Marushchak O.","year":"2021","unstructured":"Marushchak O.; Yakubov R.; Yakubov R.; Goldenberg G.; Review on novel oral therapies for Psoriasis. J Clin Aesthet Dermatol  2021,14(12),55-63","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1007\/s13555-021-00632-7","volume":"11","author":"Bissonnette R.","year":"2021","unstructured":"Bissonnette R.; Maari C.; Tsianakas A.; A randomized, double-blind, placebo-controlled, phase 2a study to evaluate the efficacy and safety of RIST4721 in subjects with Palmoplantar Pustulosis. Dermatol Ther  2021,11(6),2179-2193","journal-title":"Dermatol Ther"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"103465","DOI":"10.1016\/j.drudis.2022.103465","volume":"28","author":"Tomar Y.","year":"2023","unstructured":"Tomar Y.; Gorantla S.; Singhvi G.; Insight into the pivotal role of signaling pathways in psoriasis pathogenesis, potential therapeutic molecules and drug delivery approaches. Drug Discov Today  2023,28(2),103465","journal-title":"Drug Discov Today"},{"key":"ref=213","first-page":"68","volume":"167","author":"Zimlich R.","year":"2023","unstructured":"Zimlich R.; Biologics Offer Great Results in Treating Psoriasis--at a Cost: Highly effective medications for severe disease are expensive and administered invasively, whereas the development of treatments for milder disease has lagged. Drug Top  2023,167(8),68-70","journal-title":"Drug Top"},{"key":"ref=214","doi-asserted-by":"publisher","first-page":"215","DOI":"10.4155\/tde-2019-0003","volume":"10","author":"Timmins P.","year":"2019","unstructured":"Timmins P.; Industry update: the latest developments in the field of therapeutic delivery, 1\u201331 December 2018. Ther Deliv  2019,10(4),215-226","journal-title":"Ther Deliv"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1080\/1744666X.2023.2219897","volume":"19","author":"Drakos A.","year":"2023","unstructured":"Drakos A.; Vender R.; Torres T.; Topical roflumilast for the treatment of psoriasis. Expert Rev Clin Immunol  2023,19(9),1053-1062","journal-title":"Expert Rev Clin Immunol"},{"key":"ref=216","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jaad.2019.06.1288","volume":"82","author":"Hashim P.W.","year":"2020","unstructured":"Hashim P.W.; Chima M.; Kim H.J.; Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: A double-blind, randomized, vehicle-controlled trial. J Am Acad Dermatol  2020,82(2),360-365","journal-title":"J Am Acad Dermatol"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S0140-6736(08)61391-4","volume":"372","author":"Naidoo P.","year":"2008","unstructured":"Naidoo P.; Rambiritch V.; Voclosporin (ISA247) for plaque psoriasis. Lancet  2008,372(9642),888-889","journal-title":"Lancet"},{"key":"ref=218","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.jaad.2020.02.009","volume":"82","author":"Kim B.S.","year":"2020","unstructured":"Kim B.S.; Sun K.; Papp K.; Venturanza M.; Nasir A.; Kuligowski M.E.; Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study. J Am Acad Dermatol  2020,82(6),1305-1313","journal-title":"J Am Acad Dermatol"},{"key":"ref=219","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1111\/jdv.18263","volume":"36","author":"Zhang L.","year":"2022","unstructured":"Zhang L.; Guo L.; Wang L.; Jiang X.; The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis \u2013 A network meta\u2010analysis. J Eur Acad Dermatol Venereol  2022,36(11),1937-1946","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=220","doi-asserted-by":"publisher","first-page":"411","DOI":"10.23736\/S0392-0488.20.06658-4","volume":"155","author":"D\u2019urso D.","year":"2020","unstructured":"D\u2019urso D.; Chiricozzi A.; Pirro F.; New JAK inhibitors for the treatment of psoriasis and psoriatic arthritis. G Ital Dermatol Venereol  2020,155(4),411-420","journal-title":"G Ital Dermatol Venereol"},{"key":"ref=221","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40257-021-00618-3","volume":"22","author":"Simpson E.L.","year":"2021","unstructured":"Simpson E.L.; Silverberg J.I.; Nosbaum A.; Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program. Am J Clin Dermatol  2021,22(5),693-707","journal-title":"Am J Clin Dermatol"},{"key":"ref=222","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","volume":"392","author":"Mease P.","year":"2018","unstructured":"Mease P.; Coates L.C.; Helliwell P.S.; Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): Results from a randomised, placebo-controlled, phase 2 trial. Lancet  2018,392(10162),2367-2377","journal-title":"Lancet"},{"key":"ref=223","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/jcph.1046","volume":"58","author":"Banfield C.","year":"2018","unstructured":"Banfield C.; Scaramozza M.; Zhang W.; The safety, tolerability, pharmacokinetics, and pharmacodynamics of a TYK2\/JAK1 inhibitor (PF\u201006700841) in healthy subjects and patients with plaque psoriasis. J Clin Pharmacol  2018,58(4),434-447","journal-title":"J Clin Pharmacol"},{"key":"ref=224","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2340\/00015555-2702","volume":"97","author":"Eskeland S.","year":"2017","unstructured":"Eskeland S.; Halvorsen J.; Tanum L.; Antidepressants have anti-inflammatory effects that may be relevant to dermatology: A systematic review. Acta Derm Venereol  2017,97(8),897-905","journal-title":"Acta Derm Venereol"},{"key":"ref=225","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2165\/00003088-200746040-00002","volume":"46","author":"Rao N.","year":"2007","unstructured":"Rao N.; The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet  2007,46(4),281-290","journal-title":"Clin Pharmacokinet"},{"key":"ref=226","doi-asserted-by":"crossref","first-page":"107008","DOI":"10.1016\/j.intimp.2020.107008","volume":"89","author":"Li L","year":"2020","unstructured":"Li L; Wu Z; Wu M.; IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitis. Int Immunopharmacol  2020,89(Pt B),107008","journal-title":"Int Immunopharmacol"},{"key":"ref=227","doi-asserted-by":"publisher","first-page":"5","DOI":"10.7573\/dic.2024-5-6","volume":"13","author":"Yilmaz O.","year":"2024","unstructured":"Yilmaz O.; Pinto J.P.; Torres T.; New and emerging oral therapies for psoriasis. Drugs Context  2024,13,5-6","journal-title":"Drugs Context"},{"key":"ref=228","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","volume":"303","author":"Mrowietz U.","year":"2011","unstructured":"Mrowietz U.; Kragballe K.; Reich K.; Definition of treatment goals for moderate to severe psoriasis: A European consensus. Arch Dermatol Res  2011,303(1),1-10","journal-title":"Arch Dermatol Res"},{"key":"ref=229","doi-asserted-by":"crossref","first-page":"208.5-5.","DOI":"10.4049\/jimmunol.194.Supp.208.5","volume":"194","author":"McGeehan G","year":"2015","unstructured":"McGeehan G; Bukhtiyarov Y; Zhao Y; Meng S; Noto P; Stadanlick J; VTP-43742 is a potent and selective ROR\u03b3t blocker that demonstrates oral efficacy in a mouse model of autoimmunity through suppression of IL-17A production (THER7P.945). J Immunol  2015,194(1_Supplement),208.5-5.","journal-title":"J Immunol"},{"key":"ref=230","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1021\/acs.jmedchem.0c01698","volume":"64","author":"Liu C.","year":"2021","unstructured":"Liu C.; Lin J.; Langevine C.; Discovery of BMS-986202: A clinical Tyk2 inhibitor that binds to Tyk2 JH2. J Med Chem  2021,64(1),677-694","journal-title":"J Med Chem"},{"key":"ref=231","doi-asserted-by":"publisher","first-page":"e15703","DOI":"10.7759\/cureus.15703","volume":"13","author":"Mullangi S.","year":"2021","unstructured":"Mullangi S.; Ponnam S.; Lekkala M.R.; Koya S.; A case of de novo psoriasis secondary to nivolumab in a patient with metastatic renal cell carcinoma. Cureus  2021,13(6),e15703","journal-title":"Cureus"}],"container-title":["Recent Advances in Inflammation &amp; Allergy Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0127722708338282250309081129","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/240692\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0127722708338282250309081129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T07:42:47Z","timestamp":1776843767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/240692\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":231,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0127722708338282250309081129","relation":{},"ISSN":["2772-2708"],"issn-type":[{"value":"2772-2708","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-07-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}